Identification

Name

Mesenchymoangioblast-derived mesenchymal stem cells

Accession Number

DB15739

Description

Mesenchymoangioblast (MCA)-derived mesenchymal stem cells (MSCs) originate from the mesoderm and are a common precursor for endothelial cells. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are then able to differentiate into bone, cartilage, and adipose tissue.

The MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media. These cells have advantage over other MSCs because a large amount can be obtained from a single healthy blood donor, negating the risks from donor-and expansion dependent variability. These cells are used to treat chronic allergic airway disease and fibrosis, among other pathologies.

Type

Biotech

Groups

Investigational

Synonyms

• CYP-001

External IDs

• Mesenchymoangioblast-derived mesenchymal stem cells

Pharmacology

Indication

Not Available

Contraindications & Blackbox Warnings

Learn about our commercial Contraindications & Blackbox Warnings data.

Learn More

Pharmacodynamics

Not Available

Mechanism of action

CYP-001 is a mesenchymal stem cell (MSC) product that is created from induced pluripotent stem cells. It was developed to treat steroid-resistant acute graft-versus-host disease (GvHD), and for preclinical models of asthma, limb ischemia, cytokine release syndrome, among others. As a regenerative medicine, CYP-001 is being used as a therapeutic to treat patients with COVID-19.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Learn about our commercial Adverse Effects data.

Learn More

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Not Available

Food Interactions

Not Available

Products

Categories

Drug Categories

Not Available

Classification

Not classified

Chemical Identifiers

UNII

Not Available

CAS number

Not Available

References

General References

1. Koch JM, D'Souza SS, Schwahn DJ, Dixon I, Hacker TA: Mesenchymoangioblast-derived mesenchymal stromal cells inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in mice. Cytotherapy. 2016 Feb;18(2):219-28. doi: 10.1016/j.jcyt.2015.10.013. Epub 2015 Dec 28. [PubMed:26740280]
2. Royce SG, Mao W, Lim R, Kelly K, Samuel CS: iPSC- and mesenchymoangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid. FASEB J. 2019 May;33(5):6402-6411. doi: 10.1096/fj.201802307R. Epub 2019 Feb 15. [PubMed:30768365]
3. News Release [Link]

External Links

Not Available

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Treatment	Graft Versus Host Disease (GVHD)	1
1, 2	Recruiting	Treatment	Acute Respiratory Distress Syndrome (ARDS) / Novel Coronavirus Infectious Disease (COVID-19)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on August 11, 2020 14:48 / Updated on August 13, 2020 01:02